Deliver Your News to the World

CybeRelease: (OTC: AMZB) Announces HIV/AIDS Study


(CybeRelease, July 18, 2006) - Lake Harmony, PA - Amazon Biotech, Inc. (OTC BB:AMZB) (Frankfurt:B2D.F) today announced that it has signed an Interim Letter of Agreement with the Immunology Clinic of New York, New York to conduct a Phase I/II, randomized, double blind, placebo controlled study to test the safety and efficacy of its Botanical Drug Product AMZ0026 in pre-symptomatic HIV-positive patients undergoing no other anti-retroviral therapies.

The Immunological Disease Clinic is led by Arthur Englard, MD, PhD, Assistant Professor of Clinical Medicine at the Columbia College of Physicians and Surgeons. Dr. Englard is a specialist in Immunology and HIV medicine and, for 20 years, has been heavily involved in the AIDS Center Program at St. Lukes/Roosevelt Hospital Center (New York, NY), holding titles ranging from Fellow and Research Associate to Assistant Director. Dr. Englard is a member of Amazon Biotech’s Scientific Advisory Board.

Acting under Protocol Number AMZ0026-001b, Dr. Englard will serve as Principal Investigator, overseeing all aspects of this study at his clinical site and making presentations of the study findings following the study’s conclusion.

The Immunology Clinic is willing to enroll all of the necessary subjects for the study, however. Amazon Biotech, Inc. is currently negotiating with other potential Investigative sites, including hospital clinics, to participate in this study.

For a Free Newsletter and more information, go to

To read the complete release, go to

CybeRelease Gainers are Linktone Ltd. (Nasdaq: LTON), Natural Health Trends Corporation (Nasdaq: BHIP), Mothers Work, Inc. (Nasdaq: MWRK), StemCells, Inc. (Nasdaq: STEM), Collectors Universe, Inc. (Nasdaq: CLCT), Partner Communications Company Ltd. (Nasdaq: PTNR), Adaptec, Inc. (Nasdaq: ADPT) and Ituran Location and Control Ltd. (Nasdaq: ITRN).

CybeRelease Decliners are Logitech International S.A. (Nasdaq: LOGI), LKQ Corporation (Nasdaq: LKQX), Digitas, Inc. (Nasdaq: DTAS), Ryanair Holdings PLC (Nasdaq: RYAAY), Business Objects S.A. (Nasdaq: BOBJ), LTX Corporation (Nasdaq: LTXX), Qiagen N.V. (Nasdaq: QGEN) and ARM Holdings, plc (Nasdaq: ARMHY).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $500.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.